Presenter of 2 Presentations
IS020 - Pre-clinical development of CGM-CKM (ID 212)
Abstract
Abstract Body
The unmet need for ketone monitoring in the diabetic population is underscored by the rising incidence of Diabetic Ketoacidosis (DKA). Current solutions for ketone monitoring are expensive and cumbersome, mostly involving serial measurements of capillary blood. These solutions are insufficient for real-time monitoring of ketone levels, which is required for reducing DKA incidence. Continuous Ketone Monitoring (CKM) wearable patches are under development by several groups, employing different approaches to measure levels of the most prominent ketone - beta-hydroxybutyrate (BHB) - in the interstitial fluid (ISF). Most of these approaches rely on the enzyme BHB-dehydrogenase to specifically oxidize BHB to pyruvate while generating the co-factor NADH in the process, which is then electrochemically sensed. QuLab Medical has developed a novel minimally-invasive intradermal patch platform for continuously monitoring multiple metabolites in parallel. We are in the process of developing a novel non-enzymatic sensor for BHB sensing. Combining this sensor with a CGM in a single patch device is expected to greatly benefit T1D patients, providing them with multiple additional treatment options and empowering them to better monitor their condition and improve their overall health and well-being.
IS084 - Continuous Lactate Monitoring (CLM) – A new paradigm for monitoring high-risk diabetic patients (ID 300)
Abstract
Abstract Body
As wearable healthcare monitoring systems advance, there is great potential for multi-metabolite sensing to enhance the management of type 1 diabetes (T1D). Improvements in wearable sensor technology, specifically the introduction of additional analyte monitoring capabilities, are believed to ultimately lead to improved glycemic control. Defective glucose metabolism and low tissue oxygenation have been linked to enhanced lactate levels in diabetic patients with acute myocardial infarction (AMI). High lactate levels indicate increased risk for poor outcome in this population. The rise in blood lactate concentration in diabetics with AMI was previously shown to be associated with increased incidence of heart failure, severe arrhythmias, cardiogenic shock, and high mortality rate. QuLab Medical has developed a novel minimally-invasive intradermal patch platform for continuously monitoring multiple metabolites in parallel. Specifically, we have focused on the development of a Continuous Lactate Monitor (CLM) and combining it with a CGM in a single path device. We believe that the combined CGLM solution will help T1D patients better manage their life, on both wellness and disease fronts.